Antibody engineers seek optimal drug targeting TIGIT checkpoint

Antibody engineers seek optimal drug targeting TIGIT checkpoint

Four antibodies are already in trials to test efficacy against the emerging checkpoint molecule TIGIT, but debate swirls around the importance of Fc binding for drug action.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature biotechnology 2020-09, Vol.38 (9), p.1007-1009
1. Verfasser: Dolgin, Elie
Format: Artikel
Sprache:eng
Schlagworte:
Agriculture
Antibodies
Apoptosis
Bioinformatics
Biological products industry
Biomedical and Life Sciences
Biomedical Engineering/Biotechnology
Biomedicine
Biopharmaceutics
Biotechnology
Drug targeting
Engineers
Health aspects
Immunoglobulin G
Life Sciences
Methods
Monoclonal antibodies
News
Product development
T cells
Testing
Therapeutic targets
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Four antibodies are already in trials to test efficacy against the emerging checkpoint molecule TIGIT, but debate swirls around the importance of Fc binding for drug action.
ISSN:1087-0156
1546-1696
DOI:10.1038/s41587-020-0666-1